Multinational pharmaceutical company's semi-annual report: Yang Sen's half-year sales of this drug are $5 billion and Roche's troika suffers

In July, multinational pharmaceutical companies began to publish semi-annual reports one after another, with Johnson & Johnson, Novartis, Roche, and Bojian taking the lead in publishing

From the product point of view, Janssen Usnumab has sales of nearly US$5 billion, with strong growth and is expected to become a super blockbuster; Roche’s “troika” continues to be impacted by biosimilar drugs in H1, with the highest decline of Rituxan Monoclonal antibodies, sales of 1.

Mass vaccination in the world.

Johnson

Johnson & Johnson's total global revenue in the first half of the year was US$45.

From a product point of view, the products with the highest sales and the fastest-growing products in the first half of the year are similar to those in 2020.

Usinuzumab is a fully human monoclonal antibody that targets the p40 subunit shared by IL-12 and IL-23.

With the current growth trend, uznumab will most likely become a super blockbuster in the field of autoimmunity with another 10 billion U.

In terms of growth rate, the fastest growth rates were Apalutamide 80%, daratumumab 52.

Apalutamide was approved by the FDA in 2018 for the treatment of non-metastatic (prostate cancer cells have not spread) castration-resistant (disease progression after hormone therapy) prostate cancer.

Daratumumab is the world's first CD38 monoclonal antibody to be approved for marketing.

Novartis

Novartis's revenue in the first half of the year was US$25.

The semi-annual report showed that the non-tumor business achieved a 6% growth driven by Nuoxinto, Skuchiyuumab, gene therapy Zolgensma, Ranibizumab, and Kesimpta.

The three innovative drugs with the highest sales of Novartis are Scucuzumab at US$2.

Skukuzumab is also a drug for autoimmune diseases.

Novartis's product with the highest growth in the first half of the year was the "sky-priced" new drug Zolgensma, which was priced at US$2.

In addition, Novartis's semi-annual report also mentioned China's performance, with a total revenue of US$1.

Roche

On July 22, Roche released its H1 financial report for 2021.
The total global revenue was 30.
713 billion Swiss francs, an increase of 8% year-on-year.
Among them, the pharmaceutical sector revenue was 21.
671 billion Swiss francs, an increase of -3% year-on-year; Roche diagnostics revenue was 9.
04 billion Swiss francs, a year-on-year increase An increase of 51%
.

Relatively speaking, Roche's pharmaceutical sector in China has achieved significant growth, with revenue of 1.
7 billion Swiss francs, an increase of 3%, mainly due to Pertuzumab, Alectinib, Atelizumab and Tridizumab.
Strong sales of touzumab, but part of this was also offset by the decline in sales of bevacizumab and rituximab due to competition from biosimilar drugs
.
In addition, Roche Diagnostics has revenue of 1.
22 billion Swiss francs in China, and the two segments together account for 9.
5% of global revenue
.

From the product point of view, Roche’s performance is still affected by the competition of biosimilar drugs.
The "troika" of rituximab, bevacizumab and trastuzumab all fell by about 40% in the first half of the year.
, But on the other hand, new drug products are already driving performance.
The PPT of its financial report shows that the sales of new drugs listed after 2012 exceeded 11 billion Swiss francs, an increase of more than 30% year-on-year, and it has accounted for more than 50% of the total revenue of the pharmaceutical sector
.

Among the new drugs, the three fastest-growing products are Hemlibra, Atelizumab, and Ocrevus.
The sales in the first half of the year were 1.
393 billion Swiss francs, 1.
599 billion Swiss francs, and 2.
438 billion Swiss francs, representing a year-on-year increase of 45%.
, 29%, 23%
.

Hemlibra is a bispecific factor IXa and factor X-directed antibody that can bring together the two proteins involved in the natural coagulation cascade-coagulation factors IXa and X, and restore the coagulation process of patients with hemophilia A.
The first innovative drug approved in the past 20 years for the treatment of patients with severe hemophilia A who do not have blood coagulation factor VIII inhibitors in their bodies
.
Hemlibra’s sales in 2020 will reach 2.
19 billion Swiss francs (approximately US$2.
39 billion), an increase of 68% year-on-year.
Clarivate Analytics predicts that Hemlibra’s sales will reach US$4 billion in 2022
.

Bojian

The approval of Alzheimer's new drug made Bojian the focus of the industry in the first half of the year, but since Aduhelm was approved in June, it did not show its impact on Bojian's performance
.

Bojian's revenue in the first half of the year was 5.
469 billion U.
S.
dollars.
The product with the highest sales was its multiple sclerosis drug Tysabri at 1.
027 billion U.
S.
dollars, followed by SMA treatment drug Spinraza at 1.
02 billion U.
S.
dollars
.

In Bojian's semi-annual report, it is not the performance that attracts the most attention, but the clinical failure of two gene therapy products, which ultimately caused more than US$500 million in R&D investment
.

The first is BIIB111, which failed to effectively correct the vision of patients in the phase III trial without choroidalemia and did not reach the secondary endpoint
.
Bojian previously invested US$350 million in clinical research and development of the drug
.

Another gene therapy product that failed was BIIB112.
Receiving BIIB112 treatment failed to increase the patient's retinal sensitivity, and the proportion of patients whose eyes improved by ≥7dB from baseline did not achieve a statistically significant improvement
.

Both products were obtained when Biogen acquired the British ophthalmic gene therapy company Nightstar Therapeutics for US$877 million in March 2019
.
Bojian did not disclose further plans after the clinical failure of these two products in the semi-annual report
.

Judging from the actions of multinational pharmaceutical giants in recent years, stripping and innovation are the two major development keywords.
Although traditional therapies are still the main source of their performance, innovative therapies such as gene therapy and cell therapy have gradually become their performance growth.
At the same time, the giants have never given up on exploring more innovative fields, bringing capital into the market in areas such as mRNA and PROTAC
.